These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31738157)

  • 41. Nanostructured Delivery Systems: Augmenting the Delivery of Antiretroviral Drugs for Better Management of HIV/AIDS.
    Singh G; Pai RS; Mustafa S
    Crit Rev Ther Drug Carrier Syst; 2015; 32(6):503-33. PubMed ID: 26559551
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efavirenz Self-Nano-Emulsifying Drug Delivery System: In Vitro and In Vivo Evaluation.
    Kamble RN; Mehta PP; Kumar A
    AAPS PharmSciTech; 2016 Oct; 17(5):1240-7. PubMed ID: 26573159
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.
    Bacheler LT; Anton ED; Kudish P; Baker D; Bunville J; Krakowski K; Bolling L; Aujay M; Wang XV; Ellis D; Becker MF; Lasut AL; George HJ; Spalding DR; Hollis G; Abremski K
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2475-84. PubMed ID: 10952598
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.
    Shao J; Kraft JC; Li B; Yu J; Freeling J; Koehn J; Ho RJ
    Nanomedicine (Lond); 2016; 11(5):545-64. PubMed ID: 26892323
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial.
    Chen J; Chen R; Shen Y; Wei H; Wang X; Zhang R; Hu Z; Xie R; Huang Q; Wang J; Liu L; Qi T; Wang Z; Song W; Tang Y; Sun J; Lu H
    Emerg Microbes Infect; 2020 Dec; 9(1):843-850. PubMed ID: 32267205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
    Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
    Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of sex-by-formulation interaction in bioequivalence studies of efavirenz tablets.
    González-Rojano E; Abad-Santos F; Ochoa D; Román M; Marcotegui J; Álvarez C; Gordon J; García-Arieta A
    Br J Clin Pharmacol; 2018 Aug; 84(8):1729-1737. PubMed ID: 29633302
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insights on Oral Drug Delivery of Lipid Nanocarriers: a Win-Win Solution for Augmenting Bioavailability of Antiretroviral Drugs.
    Nabi B; Rehman S; Baboota S; Ali J
    AAPS PharmSciTech; 2019 Jan; 20(2):60. PubMed ID: 30623263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Kryst J; Kawalec P; Pilc A
    PLoS One; 2015; 10(5):e0124279. PubMed ID: 25933004
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected].
    Chiappetta DA; Hocht C; Taira C; Sosnik A
    Nanomedicine (Lond); 2010 Jan; 5(1):11-23. PubMed ID: 20025460
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges.
    Wen H; Jung H; Li X
    AAPS J; 2015 Nov; 17(6):1327-40. PubMed ID: 26276218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic Applications of Curcumin Nanoformulations.
    Yallapu MM; Nagesh PK; Jaggi M; Chauhan SC
    AAPS J; 2015 Nov; 17(6):1341-56. PubMed ID: 26335307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nanocapsules for Drug Delivery: An Updated Review of the Last Decade.
    Erdoğar N; Akkın S; Bilensoy E
    Recent Pat Drug Deliv Formul; 2018; 12(4):252-266. PubMed ID: 30674269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy.
    Brundage RC; Yong FH; Fenton T; Spector SA; Starr SE; Fletcher CV
    Antimicrob Agents Chemother; 2004 Mar; 48(3):979-84. PubMed ID: 14982792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of antiretroviral regimen on viral suppression among pregnant women living with HIV in Brazil.
    Pascom ARP; Fonseca FF; Pinho RGG; Perini FB; Pereira G; Avelino-Silva VI
    Int J STD AIDS; 2020 Aug; 31(9):903-910. PubMed ID: 32702281
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The progress of novel drug delivery systems].
    Gao HL; Jiang XG
    Yao Xue Xue Bao; 2017 Feb; 52(2):181-8. PubMed ID: 29979498
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nano-carriers for the Treatment of Tuberculosis.
    Gilani SJ; Ameeduzzafar ; Jafar M; Shakil K; Imam SS
    Recent Pat Antiinfect Drug Discov; 2017; 12(2):95-106. PubMed ID: 28595544
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz.
    Avachat AM; Parpani SS
    Colloids Surf B Biointerfaces; 2015 Feb; 126():87-97. PubMed ID: 25543986
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nanocarriers as Tools in Delivering Active Compounds for Immune System Related Pathologies.
    Soica C; Coricovac D; Dehelean C; Pinzaru I; Mioc M; Danciu C; Fulias A; Puiu M; Sitaru C
    Recent Pat Nanotechnol; 2016; 10(2):128-45. PubMed ID: 27502390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.